Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study.

Journal for ImmunoTherapy of Cancer(2023)

引用 0|浏览1
暂无评分
摘要
NCT02535078.
更多
查看译文
关键词
metastatic cutaneous melanoma,durvalumab,tremelimumab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要